We are live on ! Find out more
LFCR icon

Lifecore Biomedical
LFCR

86 hedge funds and large institutions have $221M invested in Lifecore Biomedical in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 18 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 18

16% more capital invested

Capital invested by funds: $190M → $221M (+$30.6M)

0.38% more ownership

Funds ownership: 66.19% → 66.57% (+0.38%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1% less funds holding

Funds holding: 87 → 86 (-1)

36% less call options, than puts

Call options by funds: $76K | Put options by funds: $118K

Holders
86
Holders Change
-1
Holders Change %
-1.15%
% of All Funds
1.13%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
16
Increased
34
Reduced
18
Closed
17
Calls
$76K
Puts
$118K
Net Calls
-$42K
Net Calls Change
-$39K

Top Buyers

Rank Fund Capital Flow
1
GC
Grizzlyrock Capital
Illinois
+$4.95M
2
Invesco
Invesco
Georgia
+$2.56M
3
LCM
Landscape Capital Management
New Jersey
+$920K
4
State Street
State Street
Massachusetts
+$900K
5
BlackRock
BlackRock
New York
+$741K

Top Sellers

Rank Fund Capital Flow
1
2L
22NW LP
Washington
-$10.1M
2
AWG
Alpha Wave Global
New York
-$509K
3
Goldman Sachs
Goldman Sachs
New York
-$321K
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$254K
5
Boston Partners
Boston Partners
Massachusetts
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
WC
1
Wynnefield Capital
New York
$38.2M – – –
LPAM
2
Legion Partners Asset Management
California
$36M – – –
GRIM
3
Greenhaven Road Investment Management
Connecticut
$30M +$530K +78,686 +2%
2L
4
22NW LP
Washington
$22.6M -$10.1M -1,490,981 -85%
3C
5
325 Capital
New York
$17.6M – – –
BlackRock
6
BlackRock
New York
$15.2M +$741K +109,907 +6%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.1M +$427K +63,301 +4%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$6.3M +$169K +24,995 +3%
Morgan Stanley
9
Morgan Stanley
New York
$6.01M +$76.2K +11,297 +2%
GC
10
Grizzlyrock Capital
Illinois
$5.96M +$4.95M +734,533 New
State Street
11
State Street
Massachusetts
$4.31M +$900K +133,551 +34%
DA
12
DCF Advisers
Connecticut
$3.76M -$135K -20,013 -4%
Invesco
13
Invesco
Georgia
$3.08M +$2.56M +379,413 New
Northern Trust
14
Northern Trust
Illinois
$1.98M +$55.7K +8,264 +4%
QOP
15
Quinn Opportunity Partners
Virginia
$1.64M +$329K +48,806 +32%
TAM
16
Tocqueville Asset Management
New York
$1.23M – – –
LPL Financial
17
LPL Financial
California
$1.2M +$15.4K +2,290 +2%
LCM
18
Landscape Capital Management
New Jersey
$1.11M +$920K +136,412 New
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$1.01M +$720K +106,855 +611%
UBS Group
20
UBS Group
Switzerland
$785K -$91.5K -13,566 -12%
Charles Schwab
21
Charles Schwab
California
$712K +$55.2K +8,195 +10%
GI
22
GAMCO Investors
Connecticut
$686K – – –
Bank of New York Mellon
23
Bank of New York Mellon
New York
$675K -$3.96K -587 -0.7%
Millennium Management
24
Millennium Management
New York
$550K -$223K -33,064 -33%
BCM
25
Bridgeway Capital Management
Texas
$502K – – –
1
2 3 4 5

LFCR Hedge Fund Activity: Q2 2025 in Review

86 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2025, worth a combined $221M — up 16% from $190M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LFCR and 16 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 34 added.

The largest buyer was Grizzlyrock Capital, opening a new position worth an estimated $4.95M. The largest seller was 22NW LP, cutting an estimated $10.1M.

  • 86 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2025, down from 87 in Q1 2025.
  • Funds reported $221M of Lifecore Biomedical stock for Q2 2025, up 16% quarter-over-quarter.
  • 16 funds opened new Lifecore Biomedical positions in Q2 2025 and 17 closed out, a net change of -1 holder.
  • The largest Lifecore Biomedical buyer in Q2 2025 was Grizzlyrock Capital, an estimated $4.95M added.
  • The largest Lifecore Biomedical seller in Q2 2025 was 22NW LP, an estimated $10.1M sold.

Based on aggregated 13F filings for Q2 2025.